XYWAV

Peak

calcium, magnesium, potassium, and sodium oxybates

NDAORALSOLUTIONPriority Review
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4

Clinical Trials (4)

NCT05875974Phase 4Completed

A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy

Started Jul 2023
207 enrolled
Idiopathic HypersomniaNarcolepsy
NCT05869773Phase 4Completed

A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy

Started Jun 2023
160 enrolled
Narcolepsy
NCT04803786N/ACompleted

A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy

Started Apr 2021
110 enrolled
Narcolepsy
NCT04794491Phase 4Completed

An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy

Started Mar 2021
62 enrolled
Narcolepsy

Loss of Exclusivity

LOE Date
Feb 22, 2041
182 months away
Patent Expiry
Feb 22, 2041
Exclusivity Expiry
Aug 12, 2028

Patent Records (5)

Patent #ExpiryTypeUse Code
10675258
Jan 11, 2033
U-2938
8591922
Jan 11, 2033
Product
10195168
Jan 11, 2033
Product
11554102
Jan 11, 2033
Product
9132107
Jan 11, 2033
Product